정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1332 | Not yet recruiting | HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients | COVID-19 Respiratory Infection | Drug: HC-1119 Drug: Placebo |
Phase 3 | Applied Biology, Inc., Hinova Pharmaceuticals Inc. | INDUSTRY | 602 | All | 18 Years ~ 85 Years | |
| 1331 | Not yet recruiting | HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers | Prophylaxis | Drug: Hydroxychloroquine | Phase 3 | Medical University of Vienna | OTHER | 440 | All | 18 Years | |
| 1330 | Recruiting | hCT-MSCs for COVID19 ARDS | COVID19 | Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University. Other: Placebo |
Phase 2 | Joanne Kurtzberg, MD, The Marcus Foundation | OTHER | 50 | All | 18 Years | Boca Raton Regional Hospital, Boca Raton, Florida, United States Jackson Memorial Hospital, Miami, Florida, United States University of Miami Hospital, Miami, Florida, United States New York Medical College, Valhalla, New York, United States Duke Hospital, Durham, North Carolina, United States |
| 1329 | Not yet recruiting | HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial | Hydroxychloroquine | Drug: Hydroxychloroquine Pre-Exposure Prophylaxis Drug: Placebo oral tablet |
Phase 3 | GeoSentinel Foundation | OTHER | 374 | All | 18 Years | The New York Center for Travel and Tropical Medicine, New York, New York, United States |
| 1328 | Completed | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | COVID-19 | Drug: Hydroxychloroquine Drug: Placebo oral tablet |
Phase 3 | Adrian Hernandez, Patient-Centered Outcomes Research Institute | OTHER | 1360 | All | 18 Years | Children's Hospital Colorado/University of Colorado Denver, Aurora, Colorado, United States University of Florida, Gainesville, Florida, United States University of Florida Jacksonville, Jacksonville, Florida, United States University of Florida Health Central Florida, Leesburg, Florida, United States University of Miami Florida, Miami, Florida, United States Advent Health, Orlando, Florida, United States University of South Florida, Tampa, Florida, United States Northwestern Medicine, Chicago, Illinois, United States Rush University, Chicago, Illinois, United States University of Iowa, Iowa City, Iowa, United States University of Kansas Medical Center, Kansas City, Kansas, United States University Medical Center New Orleans, New Orleans, Louisiana, United States Ochsner Clinic Foundation, New Orleans, Louisiana, United States Johns Hopkins, Baltimore, Maryland, United States University of Michigan, Ann Arbor, Michigan, United States Allina Health, Minneapolis, Minnesota, United States Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States University of Missouri-Columbia, Columbia, Missouri, United States University of Nebraska Medical Center, Omaha, Nebraska, United States Hospital for Special Surgery, New York, New York, United States Columbia University, Irving Medical Center, New York, New York, United States Weill Cornell Medicine, New York, New York, United States University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States Duke University Medical Center, Durham, North Carolina, United States Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina, United States The Ohio State University Wexner Medical Center, Columbus, Ohio, United States Temple University Hospital, Philadelphia, Pennsylvania, United States University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States Vanderbilt University Medical Center, Nashville, Tennessee, United States University of Texas Southwestern Medical Center, Dallas, Texas, United States Baylor Scott & White Medical Center-Temple, Temple, Texas, United States Seattle Children's Hospital, Seattle, Washington, United States Marshfield Clinic Health System, Marshfield, Wisconsin, United States |
| 1327 | Withdrawn | Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection | Covid19 | Drug: MPT0B640 | Phase 1 | J Ints Bio | INDUSTRY | 0 | All | 18 Years | |
| 1326 | Recruiting | HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) | Covid19 | Drug: Apixaban Drug: Atorvastatin |
Phase 3 | Cambridge University Hospitals NHS Foundation Trust, University of Liverpool, Cambridge University Hospitals NHS Foundation Trust (joint Sponsor), The University of Cambridge (joint Sponsor) | OTHER | 2631 | All | 18 Years | Addenbrookes Hospital, Cambridge, United Kingdom |